CD44 and cancer: To further explore this shift we performed FACS analysis using CD44 and CD24 surface markers to examine whether a shift from luminal to basal-like cells as characterized by lower CD24 expression and a higher CD44:CD24 ratio, a cancer stem cell index34, was evident.